Gastroenteropancreatic Neuroendocrine Tumors Clinical Trial
Official title:
Prospective Observational Study in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated With Lanreotide Depot in a US Community Oncology Setting
The purpose of this trial is to assess time to disease progression of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors treated with Lanreotide Depot. This is an observational study therefore all data collected will be in accordance with the routine practice of physicians.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02231762 -
Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
|
Phase 2 | |
| Completed |
NCT02608203 -
[68 Ga]-DOTANOC PET/CT in GEP-NETs
|
Phase 2/Phase 3 | |
| Completed |
NCT01842165 -
177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs
|
Phase 3 | |
| Completed |
NCT02630654 -
Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs
|
||
| Terminated |
NCT02078843 -
Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02162446 -
68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
|
Phase 1/Phase 2 | |
| Completed |
NCT03043664 -
Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT04524442 -
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
|
Phase 4 | |
| Active, not recruiting |
NCT04711135 -
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
|
Phase 2 |